48 results
Assess the feasibility of preoperative treatment with pertuzumab and trastuzumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of withdrawal rate from surgery
The main objectives are to evaluate the efficacy (as measured byprogression free survival at 6 months) of pertuzumab combined withtrastuzumab (PH) or PH plus metronomic chemotherapy (PHM) in anelderly metastatic breast cancer population, and to…
The primary objective of this study is to determine the efficacy of administration of aldoxorubicin compared to investigator*s choice of treatment in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have relapsed…
RO5479599 is an investigational drug which is investigated by F.Hoffmann-La Roche and the Center for Personalized Cancer Treatment for the treatment of locally advanced or metastatic solid tumors with HER3 overexpression.Substudy BP27771/IMGThe…
The purpose of this clinical research study is to compare the effect of panitumumab to cetuximab (Erbitux®) in treating metastatic colorectal cancer in patients whose tumor contains the wild-type (unchanged) KRAS gene and who have previously been…
Pertuzumab is the investigational agent being studied for the treatment of HER2-positive gastric cancer. This study is to compare the overall survival (OS) in patients treated with pertuzumab in addition to trastuzumab (Herceptin®) plus cisplatin…
Primary objective: Phase Ib: To estimate the MTD and/or RP2D of BYL719 in combination with cetuximab. Phase II: To compare the efficacy of BYL719 plus cetuximab in comparison with cetuximab monotherapy.Secondary objective (major): safety and…
The primary aim of this study is to determine the Maximum Tolerated Dose (MTD) of BIBW2992 treatment in combination with cetuximab in patients with Non-Small Cell Lung Cancer with acquired resistance to erlotinib or gefitinib.Safety,…
Primary Objective• For Arms A, B, and C: Determine the overall response rate (RR) of EZN-2208 for two distinct cohorts of patients with mCRC- Patients with mutated K-RAS tumors (Arm A)- Patients with wild-type K-RAS tumors (Arms B and C)• For Arms B…
Primary objective is to investigate the percentage of patients with k-ras mutant advanced or metastatic colorectal cancer free from progression and alive after 12.5 weeks after the first dose of cetuximab (i.e., 14 weeks after the scan at baseline…
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.
The main objective of the first part of the study is the demonstration of 89Zr-cetuximab uptake in non-hepatic tumour lesions. The main objective of the second part is the association between 89Zr-cetuximab uptake in non-hepatic tumour lesions and…
The primary objective is to select one of two platinum strategies to be used in this regimen for use as experimental arm in Phase III. This is a screening feasibility study addressing purely investigational approaches.
This study looks at the impact of RO5083945 compared to cetuximab in patients with HNSCC. The study also evaluates the behavior of these drugs within the body and their mechanism of action on head and neck tumor cells and on the immune system cells…
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with metatastatic pancreatic cancer
The aim of the study is to assess the feasibility of combined treatment of Cisplatin, Cetuximab and concurrent RT and to get insight in the clinical efficacy (for study schedule, see flow chart 1). The first phase of the study will mainly focus on…
The main objective of this pilot study is to determine the biological impact of treatment with targeted agents at the systemic and local tissue level in relation to toxicity.
PRIMARY OBJECTIVEPart 1: Safety Run-in PhaseThe primary objective for Part 1 of this study is to determine the safety and tolerability of pertuzumab in combination with either topotecan or paclitaxel.Part 2The primary objective for Part 2 of this…
To demonstrate superiority of XP chemotherapy regimen plus cetuximab versus XP alone asfirst-line treatment for advanced gastric cancer in terms of PFS. To assess cetuximab + XP versus XP alone with respect to: OS; overall response; QoL; safety.